Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy

References

• Sander JW, Shorvon SD. Epidemiology of the epilepsies. j Neural. Neumsurg. By& 61, 433–443 (1996).
   PubMed Web of Science ®Google Scholar
• Bell GS, Sander JW. The epidemiology of epilepsy: the size of the problem. Seizure 10, 306–314 (2001).
   PubMed Web of Science ®Google Scholar
• Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJ1k192, 15–23 (1999).
   Google Scholar
• Shorvon S. Handbook of 43ilepsy7ieatment Blackwell Science Ltd, London, UK (2000).
   Google Scholar
• Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet352, 1970-1973 (1998).
   Google Scholar
• Hart YM, Shorvon SD. The nature of epilepsy in the general population. II. Medical care. Epilepsy Res. 21,51–58 (1995).
   PubMedGoogle Scholar
• Brodie M. European white paper on epilepsy — call to action. Epilepsia 44\(Suppl. 6), 1–88 (2003).
   Google Scholar
• Sander RV. Some aspects of prognosis in the epilepsies: a review. Epilepsia 34,1007–1016 (1993).
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Matagne A, Gobert J, Willfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur j Pharmacol 353, 191–206 (1998).
   PubMed Web of Science ®Google Scholar
• ••Interesting results on the antiepileptogenicactivity of levetiracetam in kindling models.
   Google Scholar
• Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22,207–213 (1995).
   Google Scholar
• Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur j Pharmacol 232,147–158 (1993).
   PubMed Web of Science ®Google Scholar
• Margineanu D-G, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 42(4), 281–285 (2000).
   PubMedGoogle Scholar
• Klitgaard H, Matagne A, Grimée R, Vanneste-Goemaere J, Margineanu D-G. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 12 (2), 92–100 (2003).
   PubMed Web of Science ®Google Scholar
• •Results suggest a novel mode of action of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy.
   Google Scholar
• Angehagen M, Margineanu D-G, Ben-Menachem E, Rönnback J, Hansson E, Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform field potentials in hippocampal neurons. Neuroreport 14, 471–475 (2003).
   Google Scholar
• Löscher W Hönack D, Runfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. I Pharmacol Exp. flier 284, 474–479 (1998).
   Google Scholar
• Handbook of Epilepsy Second Edition. Browne TR, Holmes GL (Eds). Lippincott, William & Wilkins, NY, USA (2002).
   Google Scholar
• MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 34\(Suppl. 5), S1—S8 (1993).
   Google Scholar
• Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na + and T-type Ca2+ currents. Seizure 10,279–286 (2001).
   PubMed Web of Science ®Google Scholar
• Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett. 306,5-8 (2001).
   Google Scholar
• Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43, 9–18 (2002).
   Google Scholar
• Niespodziany I, Klitgaard H, Margineanu D-G. Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport 14, 1273–1276 (2003).
   Google Scholar
• •Results indicate that levetiracetam is differentiated from classical antiepiletic drugs by a relatively selective effect on collective neuronal responses, rather than on single neuron activity and suggest a potentially novel desynchronizing effect that probably contributes to its antiepileptic action.
   Google Scholar
• Coulter DA. Chronic epileptogenic cellular alterations in the limbic system after status epilepticus. Epilepsia 40\(Suppl. 11), S23—S33 (1999).
   Google Scholar
• Bloomenthal AB, Goldwater E, Pritchett DB, Harrison NL. Biphasic modulation of the strychnine-sensitive glycine receptor by Zn2+. Mal Pharmacol 46,1156–1159 (1994).
   PubMedGoogle Scholar
• De Deyn PP, D'Hooge R, Marescau B, Pei YO. Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants. Epilepsy Res. 12,87–110 (1992).
   PubMed Web of Science ®Google Scholar
• Rigo J-M, Hans G, Nguyen L etal The antiepileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. BE .1. Pharmacol 136,659–672 (2002).
   Google Scholar
• Walker MC, Sander JVV. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 46,912–914 (1996).
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology55, 236–242 (2000).
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41, 1179–1186 (2000).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41,1276–1283 (2000).
   Google Scholar
• Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res. 48,77-89 (2002).
   Google Scholar
• Betts T, Waegemans T, Crawford P A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9,80–87 (2000).
   PubMed Web of Science ®Google Scholar
• Privitera, MD, Godfroid P, Edrich P, Dose—response relationship of levetiracetam. Eur j New& 9\(Suppl. 2), 180–181 (2002).
   Google Scholar
• •Pooled results indicating a dose—response relationship of levetiracetam for seizure control.
   Google Scholar
• Krakow K, Walker M, Otoul C, Sander JVV. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology56,1772–1774 (2001).
   PubMed Web of Science ®Google Scholar
• Lhatoo SD, Solomon J, MacAvoy A, Kitchen N, Shorvon SD. Epilepsy surgery in the United Kingdom: a prospective estimate of the treatment gap. Proceedings of the 24th International Epilepsy Congress. Buenos Aires, Argentina, 42 (2001).
   Google Scholar
• Wong IC, Chadwick DW, Fenwick PB, Mawer GE, Sander SW. The long-term use of gabapentin, lamotrigine and vigabatrin in patients with chronic epilepsy. Epilepsia 40,1439–1445 (1999).
   Google Scholar
• Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 54, 153–161 (2003).
   PubMed Web of Science ®Google Scholar
• •Results from a large Phase IV study confirming the good efficacy, tolerability and safety profile of levetiracetam.
   Google Scholar
• Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12,131–135 (2003).
   Google Scholar
• Betts T, Yarrow H, Greenhill L, Barrett M. Clinical experience of marketed levetiracetam in an epilepsy clinic — a 1 year follow-up study. Seizure 12,136–140 (2003).
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Parker PG, Kelly K, Stephen LJ, Sills GJ, Brodie MJ. Clinical experience with levetiracetam: a prospective observational study. Epilepsia 43(7), 196–197 (2002).
   PubMedGoogle Scholar
• Dinkelacker V, Died T, Widman G, Lengler U, Elger C. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy fkhav 4, 537–547 (2003).
   Google Scholar
• Shorvon SD, van Rijckevorsel K. A new antiepileptic drug. I Neural. Neurosurg. Psych. 72,426-428 (2002). Erratum. J. Neural. Neurosurg Psych. 73,102 (2002).
   Google Scholar
• Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Thec 85,77–85 (2000).
   PubMed Web of Science ®Google Scholar
• Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 18,249–260 (1994).
   PubMed Web of Science ®Google Scholar
• Swingler RJ, Davidson DL, Roberts RC, Moulding E The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 3,115–120 (1994).
   PubMedGoogle Scholar
• Cramer JA, Arrigo C, Van Hammee G, Gauer IJ, Cereghino JJ. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41(7), 868–874 (2000).
   PubMed Web of Science ®Google Scholar
• Godfroid P, Hart Y, Roberts R, Le Loner J. Seizure freedom in patients treated with adjunctive levetiracetam: economic evaluation within the NHS. Neumlogy6(1), 433–434 (2003).
   Google Scholar
• Begley CE, Annegers JF, Lairson DR, Reynolds TE Methodological issues in estimating the cost of epilepsy. Epilepsy Res. 33,39–55 (1999).
   PubMed Web of Science ®Google Scholar
• Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of a patient-based and a population-based estimates. Neuroepidemiology19, 87–99 (2000).
   PubMed Web of Science ®Google Scholar
• Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35(6), 1230–1243 (1994).
   PubMed Web of Science ®Google Scholar
• Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 18,249–260 (1994).
   PubMed Web of Science ®Google Scholar
• British National Formulary. British Medical Association and the Royal Pharmaceutical Society, London, UK (2001).
   Google Scholar
• Department of Health. Prescription Cost Analysis 2000 (2001).
   Google Scholar
• Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: fmdings from a UK regional study. Epilepsia 39,776–786 (1998).
   PubMed Web of Science ®Google Scholar
• Beran RG. The burden of epilepsy for the patient: the intangible costs. Epilepsia 40\(Suppl. 8), 40–43 (1999).
   Google Scholar
• ••Interesting paper on the intangible costs of the illness.
   Google Scholar
• Clinical Standards Advisory Group. Services for patients with epilepsy. London, HMSO. (1999).
   Google Scholar
• Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology5, 1026–1033 (1998).
   Google Scholar